Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities.
Inetetamab (20 mg/kg, i.p.) shows antitumor effects in the JIMT-1 xenograft mouse model[2]. Inetetamab (20 mg/kg, i.p.) together with Pyrotinib or Cyclophosphamide also has distinct antitumor effects in JIMT-1 and NCI-N87 xenograft mouse model[2].
References:
[1]. Min Yan, et al. Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: A single-arm, multicenter, phase 2 study. Journal of Clinical Oncology. 2022. 40 (16), e13030-e13030. [2]. Deng L,et al. Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers. Open Life Sci. 2023 Jan 10;18(1):20220535.